COCP vs. SYBX, BIVI, APM, VBIV, INDP, KALA, IBIO, LUMO, MEIP, and TLPH
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Synlogic (SYBX), BioVie (BIVI), Aptorum Group (APM), VBI Vaccines (VBIV), Indaptus Therapeutics (INDP), KALA BIO (KALA), iBio (IBIO), Lumos Pharma (LUMO), MEI Pharma (MEIP), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry.
Cocrystal Pharma (NASDAQ:COCP) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
Synlogic received 309 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.86% of users gave Cocrystal Pharma an outperform vote while only 69.54% of users gave Synlogic an outperform vote.
Cocrystal Pharma has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Synlogic has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500.
Cocrystal Pharma has a net margin of 0.00% compared to Synlogic's net margin of -2,284.65%. Cocrystal Pharma's return on equity of -61.61% beat Synlogic's return on equity.
Cocrystal Pharma has higher earnings, but lower revenue than Synlogic. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 8.0% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Synlogic had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Synlogic and 2 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 1.25 beat Synlogic's score of 0.92 indicating that Cocrystal Pharma is being referred to more favorably in the media.
Cocrystal Pharma currently has a consensus price target of $10.00, suggesting a potential upside of 362.96%. Synlogic has a consensus price target of $65.00, suggesting a potential upside of 3,988.05%. Given Synlogic's higher probable upside, analysts clearly believe Synlogic is more favorable than Cocrystal Pharma.
Summary
Cocrystal Pharma beats Synlogic on 10 of the 16 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
